title: Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP Inhibition as a Strategy to Reduce Cardiovascular Risk: The Pro Case.
authors.affiliation: From Centre for Vascular Research, University of New South Wales, Sydney, Australia (P.J.B., K.-A.R.); South Australian Health and Medical Research Institute, University of Adelaide, South Australia (S.J.N.); Academic Medical Center, Amsterdam, The Netherlands (J.J.P.K.). pbarter@ozemail.com.au p.barter@unsw.edu.au.
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Barter
authors.affiliation: From Centre for Vascular Research, University of New South Wales, Sydney, Australia (P.J.B., K.-A.R.); South Australian Health and Medical Research Institute, University of Adelaide, South Australia (S.J.N.); Academic Medical Center, Amsterdam, The Netherlands (J.J.P.K.).
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Nicholls
authors.affiliation: From Centre for Vascular Research, University of New South Wales, Sydney, Australia (P.J.B., K.-A.R.); South Australian Health and Medical Research Institute, University of Adelaide, South Australia (S.J.N.); Academic Medical Center, Amsterdam, The Netherlands (J.J.P.K.).
authors.forename: John J P
authors.initials: JJ
authors.lastname: Kastelein
authors.affiliation: From Centre for Vascular Research, University of New South Wales, Sydney, Australia (P.J.B., K.-A.R.); South Australian Health and Medical Research Institute, University of Adelaide, South Australia (S.J.N.); Academic Medical Center, Amsterdam, The Netherlands (J.J.P.K.).
authors.forename: Kerry-Anne
authors.initials: KA
authors.lastname: Rye
mesh_terms: D000577:Amides; D000818:Animals; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000453:epidemiology* / Q000503:physiopathology / Q000517:prevention & control*; D053480:Cholesterol Ester Transfer Proteins / Q000037:antagonists & inhibitors* / Q000172:deficiency / Q000235:genetics / Q000502:physiology*; D004195:Disease Models, Animal; D004952:Esters; D006801:Humans; D008052:Lipid Metabolism, Inborn Errors / Q000235:genetics / Q000503:physiopathology; D051379:Mice; D023303:Oxazolidinones / Q000627:therapeutic use; D011804:Quinolines / Q000627:therapeutic use; D011817:Rabbits; D012307:Risk Factors; D013438:Sulfhydryl Compounds / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000577:Amides; D000924:Anticholesteremic Agents; C506642:CETP protein, human; D053480:Cholesterol Ester Transfer Proteins; D004952:Esters; D023303:Oxazolidinones; D011804:Quinolines; D013438:Sulfhydryl Compounds; D001569:Benzodiazepines; C411602:dalcetrapib; C483909:torcetrapib; C568301:evacetrapib; C530884:anacetrapib